Immunome Inc.

14 days ago · businesswire.com

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a clinical-stage target oncology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on September 1, 2026, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 86,500 shares of common stock to four new employees under the Co.

20 days ago · businesswire.com

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a clinical-stage targeted oncology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Immunome management will present at H.C. Wainwright's 28th Annual Global Investment Conference on September 14, 2026, at 11:00 a.m. ET.Interested parties can access the live audio webcast of the presentation from the Investor Relations section of the company's website at www.immunome.com.

1 month ago · marketbeat.com

argenx NASDAQ: ARGX reported positive top-line results from its Phase III ALKIVIA trial of VYVGART Hytrulo in autoimmune myositis, meeting its primary endpoint in a combined population of patients with immune-mediated necrotizing myopathy, or IMNM, and dermatomyositis, or DM.

1 month ago · globenewswire.com

Study met primary endpoint of mean Total Improvement Score (TIS) at Week 52 in the combined study population of IMNM and DM patients (p=0.0011) Patient improvements observed early and sustained throughout study; consistent treatment effect across IMNM and DM First Phase 3 study to show statistically significant and clinically meaningful improvements in disease activity in IMNM, a subtype with no approved therapy argenx to host a conference call on August 17 th at 2:30 PM CET/ 8:30 AM ET August 17, 2026, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology innovation company, today announced positive topline results from the ALKIVIA Phase 3 study evaluating VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) in adults with autoimmune myositis. Study met its primary endpoint (p=0.0011) In the combined immune-mediated necrotizing myopathy (IMNM) and dermatomyositis (DM) population, patients treated with efgartigimod demonstrated statistically significant and clinically meaningful 15.4-point greater improvement in mean Total Improvement Score (TIS) at Week 52 versus placebo (47.95 vs 32.56).

1 month ago · seekingalpha.com

I am maintaining my "Strong Buy" rating on Immunome (IMNM). This decision is driven by FDA acceptance of varegacestat's NDA and a PDUFA date set for April 2027. The company's pipeline is diversified, with IM-1021 [ROR1 ADC] in phase 1 for B-cell lymphoma/solid tumors and initial data expected in 2026. The proprietary HC74 TOP1i payload in IM-1021 aims for best-in-class efficacy, targeting resistance and bystander effects beyond Merck's ROR1 ADC.

2 months ago · businesswire.com

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced that the first patient has been dosed in the Phase 1, first-in-human trial of IM-3050, an investigational FAP-targeted radioligand therapy being evaluated in patients with FAP-expressing advanced solid tumors.“FAP is a high-potential target with expression in 75% of solid tumors,” said Bob Lechleider, M.D., Chi.

2 months ago · fool.com

An Immunome insider sold 100,000 shares for $2.4 million based on weighted average prices on July 6, 2026 and July 7, 2026. The transaction represents 32% of the insider's total equity holdings in the company.

2 months ago · zacks.com

IMNM jumps 32% in a month. This comes as the FDA accepts varegacestat's NDA for desmoid tumors, with an approval decision expected by April 2027.

3 months ago · businesswire.com

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced the U.S. Food and Drug Administration (FDA or the Agency) has accepted its New Drug Application (NDA) for varegacestat, an investigational, oral, once-daily gamma secretase inhibitor (GSI), for the treatment of adults with desmoid tumors. The FDA assigned a Prescription Drug User Fee Act (PDUFA) target action.

3 months ago · gurufocus.com

[url="]Immunome, Inc.[/url] (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today a